AA
KRYS icon

ALPS Advisors’s Krystal Biotech KRYS Stock Holding History

ALPS Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$756K Buy
2,035
+35
+2% +$10.5K ﹤0.01% 781
2026
Q1 		$517K Buy
+2,000
New +$532K ﹤0.01% 754
2025
Q4 		– Sell
-13,367
Closed -$2.36M – 1039
2025
Q3 		$2.36M Sell
13,367
-4,095
-23% -$613K 0.01% 351
2025
Q2 		$2.4M Buy
17,462
+15,542
+809% +$2.28M 0.01% 339
2025
Q1 		$346K Buy
+1,920
New +$323K ﹤0.01% 812
2024
Q4 		– Sell
-22,372
Closed -$4.07M – 1022
2024
Q3 		$4.07M Buy
22,372
+102
+0.5% +$19.7K 0.03% 258
2024
Q2 		$4.09M Buy
+22,270
New +$3.74M 0.03% 248
2023
Q4 		– Sell
-20,620
Closed -$2.39M – 994
2023
Q3 		$2.39M Buy
20,620
+384
+2% +$46.8K 0.02% 299
2023
Q2 		$2.38M Buy
20,236
+3,259
+19% +$333K 0.02% 282
2023
Q1 		$1.36M Sell
16,977
-467
-3% -$36.7K 0.01% 381
2022
Q4 		$1.38M Buy
17,444
+3,403
+24% +$253K 0.01% 378
2022
Q3 		$979K Sell
14,041
-1,170
-8% -$84.5K 0.01% 473
2022
Q2 		$999K Sell
15,211
-10,702
-41% -$666K 0.01% 476
2022
Q1 		$1.72M Sell
25,913
-2,906
-10% -$181K 0.02% 246
2021
Q4 		$2.02M Buy
28,819
+1,606
+6% +$93.5K 0.02% 288
2021
Q3 		$1.42M Sell
27,213
-2,028
-7% -$120K 0.01% 355
2021
Q2 		$1.99M Sell
29,241
-6,413
-18% -$448K 0.02% 330
2021
Q1 		$2.75M Buy
35,654
+111
+0.3% +$8.07K 0.03% 226
2020
Q4 		$2.13M Buy
35,543
+10,467
+42% +$523K 0.02% 260
2020
Q3 		$1.08M Buy
25,076
+1,357
+6% +$58.9K 0.02% 346
2020
Q2 		$982K Sell
23,719
-7,751
-25% -$373K 0.01% 316
2020
Q1 		$1.36M Sell
31,470
-3,366
-10% -$176K 0.02% 242
2019
Q4 		$1.93M Buy
34,836
+348
+1% +$17.1K 0.02% 230
2019
Q3 		$1.2M Buy
34,488
+4,260
+14% +$190K 0.01% 273
2019
Q2 		$1.22M Sell
30,228
-4,623
-13% -$151K 0.01% 286
2019
Q1 		$1.15M Buy
34,851
+1,507
+5% +$35.5K 0.01% 297
2018
Q4 		$693K Buy
+33,344
New +$698K 0.01% 396

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ALPS Advisors's KRYS Position: Q2 2026 in Review

ALPS Advisors increased its Krystal Biotech (KRYS) stake by 1.8% in Q2 2026, buying an estimated $10.5K and bringing the position to 2,035 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #781.

ALPS Advisors first reported a position in KRYS in Q4 2018 and has held it in 27 quarters since. The position peaked at $4.09M in Q2 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • ALPS Advisors held 2,035 shares of Krystal Biotech worth $756K as of Q2 2026.
  • ALPS Advisors bought 35 Krystal Biotech shares in Q2 2026, an estimated $10.5K.
  • Krystal Biotech made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #781 holding.
  • ALPS Advisors first reported a position in Krystal Biotech in Q4 2018 and has held it in 27 quarters since.
  • ALPS Advisors's Krystal Biotech position peaked at $4.09M in Q2 2024.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.